PHASE Ib CLINICAL TRIAL FOR AMD YIELDS PROMISING RESULTS.

Image via Wikipedia

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc. have announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of age-related macular degeneration (AMD). According to a press release from Mystic, the preliminary results indicated that MacuCLEAR's MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Trial participants used Mystic's VersiDoser ophthalmic delivery system to self-administer MC-1101 to the front of the eye during the trial. A key finding of the study was the successful migration of the drug to the back of the eye and the study included Proof of Concept (“POC”) indicators.

Posted in: Clinical Trial, Conditions and Diseases, Eye Disorders, Health, Macular Degeneration, Retina